Vaccination and auto-immune rheumatic diseases: Lessons learnt from the 2009 H1N1 influenza virus vaccination campaign

Current Opinion in Rheumatology

Volumn 25, Issue 2, 2013, Pages 164-170

  Touma, Zahi ^a   Gladman, Dafna D ^a   Urowitz, Murray B ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

H1N1 vaccination; HIN1; rheumatic diseases

Indexed keywords

ABATACEPT; CARDIOLIPIN ANTIBODY; CELL NUCLEUS ANTIGEN; INFLUENZA VACCINE; METHOTREXATE; PREDNISONE; RITUXIMAB;

2009 H1N1 INFLUENZA; ANKYLOSING SPONDYLITIS; ANTIBODY RESPONSE; DIFFUSE SCLERODERMA; DISEASE ACTIVITY; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HUMAN; HUMORAL IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; INFLUENZA VACCINATION; MORTALITY; PATIENT SAFETY; PRIORITY JOURNAL; REVIEW; RHEUMATIC DISEASE; SEASONAL INFLUENZA; SEROCONVERSION; SPONDYLARTHRITIS; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ANTIBODIES, VIRAL; ANTIRHEUMATIC AGENTS; AUTOIMMUNE DISEASES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; PANDEMICS; RHEUMATIC DISEASES; TREATMENT OUTCOME; VACCINATION;

EID: 84873360287     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0b013e32835d2b7b     Document Type: Review

References (37)

1. Falagas ME, Manta KG, Betsi GI, Pappas G. Infection-related morbidity and mortality in patients with connective tissue diseases: a systematic review. Clin Rheumatol 2007; 26:663-670.
2. Van Assen S, Elkayam O, Agmon-Levin N, et al. Vaccination in adult patients with auto-immune inflammatory rheumatic diseases: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for vaccination in adult patients with auto-immune inflammatory rheumatic diseases. Autoimmun Rev 2011; 10: 341-352.
3. Gladman DD, Hussain F, Ibanez D, Urowitz MB. The nature and outcome of infection in systemic lupus erythematosus. Lupus 2002; 11:234-239.
4. Urowitz MB, Gladman DD, Abu-Shakra M, Farewell VT. Mortality studies in systemic lupus erythematosus: results from a single center. III. Improved survival over 24 years. J Rheumatol 1997; 24:1061-1065.
5. Urowitz MB, Anton A, Ibanez D, Gladman DD. Autoantibody response to adjuvant and nonadjuvant H1N1 vaccination in systemic lupus erythemato-sus. Arthritis Care Res 2011; 63:1517-1520.
6. Taubenberger JK, Morens DM. Influenza: the once and future pandemic. Public Health Rep 2010; 125 (Suppl 3):16-26.
7. Polkinghorne B, Ward K, Totaro R. Pandemic (H1N1) 2009 influenza. N S W Public Health Bull 2010; 21:41-42.
8. Diez-Domingo J, Garces-Sanchez M, Baldo JM, et al. Immunogenicity and safety of H5N1A/Vietnam/1194/2004 (Clade 1) AS03-adjuvanted pre-pandemic candidate influenza vaccines in children aged 3 to 9 years: a phase II, randomized, open, controlled study. Pediatr Infect Dis J 2010; 29:e35-e46.
9. Schwarz TF, Horacek T, Knuf M, et al. Single dose vaccination with AS03-adjuvanted H5N1 vaccines in a randomized trial induces strong and broad immune responsiveness to booster vaccination in adults. Vaccine 2009; 27:6284-6290.
10. Shoenfeld Y, Agmon-Levin N. 'ASIA': autoimmune/inflammatory syndrome induced by adjuvants. J Autoimmun 2011; 36:4-8.
11. Adler S, Krivine A, Weix J, et al. Protective effect of A/H1N1 vaccination in immune-mediated disease: a prospectively controlled vaccination study. Rheumatol 2012; 51:695-700.
12. Aikawa NE, Campos LMA, Silva CA, et al. Glucocorticoid: major factor for reduced immunogenicity of 2009 influenza A (H1N1) vaccine in patients with juvenile autoimmune rheumatic disease. J Rheumatol 2012; 39:167-173.
13. Perdan-Pirkmajer K, Thallinger GG, Snoj N, et al. Autoimmune response following influenza vaccination in patients with autoimmune inflammatory rheumatic disease. Lupus 2012; 21:175-183.
14. Vista ES, Crowe SR, Thompson LF, et al. Influenza vaccination can induce new-onset anticardiolipins but not beta2-glycoprotein-I antibodies among patients with systemic lupus erythematosus. Lupus 2012; 21:168-174.
15. Gabay C, Bel M, Combescure C, et al. Impact of synthetic and biologic disease-modifying antirheumatic drugs on antibody responses to the AS03-adjuvanted pandemic influenza vaccine: a prospective, open-label, parallel-cohort, single-centerstudy. Arthritis Rheum 2011; 63:1486-1496.
16. Saad CGS, Borba EF, Aikawa NE, et al. Immunogenicity and safety of the 2009 nonadjuvanted influenza A/H1N1 vaccine in a large cohort of auto-immune rheumatic diseases. Ann Rheum Dis 2011; 70:1068-1073.
17. Lu CC, Wang YC, Lai JH, et al. A/H1N1 influenzavaccination in patientswith systemic lupus erythematosus: safety and immunity. Vaccine 2011; 29:444-450.
18. Holvast A, de Haan A, van Assen S, et al. Cell-mediated immune responsesto influenza vaccination in Wegener's granulomatosis. Ann Rheum Dis 2010; 69:924-927.
19. Abu-Shakra M, Press J, Sukenik S, Buskila D. Influenza virus vaccination of patients with SLE: effects on generation of autoantibodies. Clin Rheumatol 2002; 21:369-372.
20. Abu-Shakra M, Press J, Varsano N, et al. Specific antibody response after influenza immunization in systemic lupus erythematosus. J Rheumatol 2002; 29:2555-2557.
21. Petri M. Dermatologic lupus: Hopkins Lupus Cohort. Semin Cutan Med Surg 1998; 17:219-227.
22. Herron A, Dettleff G, Hixon B, et al. Influenza vaccination in patients with rheumatic diseases. Safety and efficacy. JAMA 1979; 242:53-56.
23. Elkayam O, Bashkin A, Mandelboim M, et al. Theeffectofinfliximab and timing of vaccination on the humoral response to influenza vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. Semin Arthritis Rheum 2010; 39:442-447.
24. Kapetanovic MC, Saxne T, Nilsson JA, Geborek P. Influenza vaccination as model fortesting immune modulation induced by anti-TNF and methotrexate therapy in rheumatoid arthritis patients. Rheumatol 2007; 46:608-611.
25. Crowe SR, Merrill JT, Vista ES, et al. Influenzavaccination responses in human systemic lupus erythematosus: impact of clinical and demographic features. Arthritis Rheum 2011; 63:2396-2406.
26. Setti M, Fenoglio D, Ansaldi F, et al. Flu vaccination with a virosomal vaccine does not affect clinical course and immunological parameters in scleroderma patients. Vaccine 2009; 27:3367-3372.
27. Bardage C, Persson I, Ortqvist A, et al. Neurological and autoimmune disorders after vaccination against pandemic influenza A (H1N1) with a monovalent adjuvanted vaccine: population based cohort study in Stockholm, Sweden. BMJ 2011; 343:d5956.
28. De Wals P, Deceuninck G, Toth E, et al. Risk of Guillain-Barre syndrome following H1N1 influenza vaccination in Quebec. JAMA 2012; 308:175-181.
29. Petri M. 1998 update on antiphospholipid antibodies. Curr Opin Rheumatol 1998; 10:426-430.
30. Petri M. Hydroxychloroquine: past, present, future. Lupus 1998; 7:65-67.
31. Vardakas KZ, Falagas ME. Interpretation of the findings of a cohort study of bacteremic patients with community-acquired pneumonia. Chest 2007; 132:1715; author reply 15-16.
32. Soriano A, Verrecchia E, Marinaro A, et al. Giant cell arteritis and polymyalgia rheumatica after influenza vaccination: report of 10 cases and review of the literature. Lupus 2012; 21:153-157.
33. Black S, Eskola J, Siegrist C-A, et al. Importance of background rates of disease in assessment of vaccine safety during mass immunisation with pandemic H1N1 influenza vaccines. Lancet 2009; 374:2115-2122.
34. Wu J, Xu F, Lu L, et al. Safety and effectiveness of a 2009 H1N1 vaccine in Beijing. N Engl J Med 2010; 363:2416-2423.
35. Centers for Disease Control and Prevention. Safety of influenza A (H1N1) 2009 monovalent vaccines-United States, October 1-November 24, 2009. MMWR Morb Mortal Wkly Rep 2009; 58:1351-1356.
36. Sowden E, Mitchell WS. An audit of influenza and pneumococcal vaccination in rheumatology outpatients. BMC Musculoskelet Disord 2007; 8:58.
37. Pradeep J, Watts R, Clunie G. Audit on the uptake of influenza and pneu-mococcal vaccination in patients with rheumatoid arthritis. Ann Rhumatic Dis 2007; 66:837-838.